SCHEMBL698742

SCHEMBL698742

NC(=O)c1cccc(C(N)=O)c1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 2/20 0.61
MAPT P10636 1/20 0.61
HPGD P15428 1/20 0.61
TSHR P16473 1/20 0.61
HSD17B10 Q99714 1/20 0.61
METAP2 P50579 1/20 0.50
GAA P10253 1/20 0.48
MMP2 P08253 1/20 0.48
BCAT2 O15382 1/20 0.48
CXCR2 P25025 1/20 0.47
PARP1 P09874 5/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
PDPK1 O15530 1/20 0.47
ERN1 O75460 1/20 0.45
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
PLK4 O00444 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3723645 0.97 KDM4E (0.58) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL2174138 0.89 KDM4E (0.50) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL424097 0.87 KDM4E (0.67) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL29552052 0.87 KDM4E (0.67) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL2019650 0.85 MMP2 (0.69) KDM4EALDH1A1MAPTHPGDTSHR
Ammonia Solution, Strong SCHEMBL8664317 0.85 KDM4E (0.64) KDM4EALDH1A1MAPTHPGDTSHR
Hydrochloric Acid SCHEMBL9377889 0.85 KDM4E (0.64) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL7332953 0.85 KDM4E (0.52) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL11651879 0.85 KDM4E (0.47) KDM4EALDH1A1MAPTHPGDTSHR
Cresotamide SCHEMBL1806785 0.84 ALDH1A1 (0.67) KDM4EALDH1A1MAPTHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115287056-B Preparation and application of natural annular molecular efficient fluorescence sensor 青岛大学 2024-06-11 CN claimed
CN-116903581-A SHP2/HDAC double-target inhibitor and preparation method and application thereof 山东大学 2023-10-20 CN claimed
CN-115521228-B BChE and HDAC double-target inhibitor and preparation method and application thereof 中国药科大学 2023-08-22 CN claimed
CN-115521228-A BChE and HDAC double-target inhibitor and preparation method and application thereof 中国药科大学 2022-12-27 CN claimed
CN-115287056-A Preparation and application of natural annular molecule efficient fluorescence sensor 青岛大学 2022-11-04 CN claimed
EP-2217928-A2 ALTERNATE LABELING STRATEGIES FOR SINGLE MOLECULE SEQUENCING Pacific Biosciences of California, Inc. (US) 2010-08-18 EP claimed
US-20090208957-A1 Alternate labeling strategies for single molecule sequencing PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2009-08-20 US claimed
WO-2009073201-A2 ALTERNATE LABELING STRATEGIES FOR SINGLE MOLECULE SEQUENCING PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2009-06-11 WO claimed
EP-1792185-A2 LANTHANIDE-BASED SUBSTRATES AND METHODS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY Allergan, Inc. (US) 2007-06-06 EP claimed
WO-2006033843-A2 LANTHANIDE-BASED SUBSTRATES AND METHODS FOR DETERMINING CLOSTRIDIAL TOXIN ACTIVITY ALLERGAN, INC. (US) 2006-03-30 WO claimed
US-20060063221-A1 Lanthanide-based substrates and methods for determining clostridial toxin activity ALLERGAN, INC. 2006-03-23 US claimed
CN-116283955-B Compound for targeted degradation of HDAC7, and preparation method and application thereof 浙江大学 2025-06-17 CN disclosed
US-20250084303-A1 Complexes and Ligands THE GENERAL HOSPITAL CORPORATION 2025-03-13 US disclosed
US-12134721-B2 Complexes and ligands THE GENERAL HOSPITAL CORPORATION (US) 2024-11-05 US disclosed
EP-4424686-A1 COMPLEXES AND LIGANDS The General Hospital Corporation (US) 2024-09-04 EP disclosed
EP-1154990-A1 PHTHALAMIDE-LANTHANIDE COMPLEXES FOR USE AS LUMINESCENT MARKERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-11-21 EP disclosed
WO-2000048990-A1 PHTHALAMIDE-LANTHANIDE COMPLEXES FOR USE AS LUMINESCENT MARKERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-08-24 WO disclosed
US-5629406-A AMINO ACID DERIVATIVES SANKYO COMPANY, LIMITED (JP) 1997-05-13 US disclosed
EP-0587311-A1 Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1994-03-16 EP disclosed
EP-0387106-A1 Novel diamine compounds, production of the same and polyamideimide resins produced therefrom TOMOEGAWA PAPER CO. LTD. (JP) 1990-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084303-A1 Complexes and Ligands BID, CLTB, NECTIN4 KDM4E 4822/4885ALDH1A1 3131/4885MAPT 2617/4885
US-12134721-B2 Complexes and ligands BID, CLTB, NECTIN4 KDM4E 4822/4885ALDH1A1 3131/4885MAPT 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.